Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update
NMRA•Second-quarter results and business update
Aug. 14 (Reuters) - Neumora Therapeutics Inc. NMRA.O:
- Neumora Therapeutics reports second quarter 2026 financial results and provides business update
- Neumora Therapeutics appoints Joshua Pinto as president and CEO and board member
- Neumora Therapeutics - Paul L. Berns to serve as executive chair
- Neumora Therapeutics - Q2 2026 net loss $43.10 million versus $52.70 million in Q2 2025
